Acrivon Therapeutics, Inc. Overview
Pro stress-test →Acrivon is a clinical stage biopharmaceutical company discovering and developing precision oncology medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, with recent data showing strong activity particularly in serous endometrial cancer.
Strategic Profile
Pro stress-test →Acrivon is currently advancing its lead program, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for endometrial cancer, and has received Fast Track designation from the FDA. The FDA has granted a Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of patients with endometrial cancer who may benefit from ACR-368 treatment. The company leverages proprietary biomarker-driven precision medicine to differentiate its approach in competitive oncology markets.
Competitive Landscape
Pro stress-test →Acrivon competes in precision oncology oncology space against larger biotech and pharma companies developing CHK1/CHK2 inhibitors and WEE1 inhibitors. Key differentiator is the proprietary phosphoproteomics-based companion diagnostic (OncoSignature) enabling biomarker-driven patient selection. Competitors include emerging biotech focused on cell cycle checkpoint inhibition and gynecological oncology specialists.
Industry Context
Acrivon Therapeutics, Inc. operates in Precision Oncology / Biopharmaceuticals.
Key facts
Founded: 2018 · Headquarters: Watertown, Massachusetts · Employees: Unknown · Revenue: Pre-revenue · Market cap: $77M